On September 28, 2021 Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported the closing of its previously announced underwritten public offering (Press release, Onconova, SEP 28, 2021, View Source [SID1234590469]). A total of 5,000,000 shares of its common stock were sold at a public offering price of $4.20 per share. The gross proceeds of the offering to the Company are $21 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Onconova granted the underwriters a thirty-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Securities is acting as sole book-running manager. Ladenburg Thalmann & Co. Inc. and Noble Capital Markets, Inc. are acting as co-managers for the offering.

The securities described above were offered by Onconova pursuant to a shelf registration statement on Form S-3 (File No. 333-237844) which was initially filed by the Company with the Securities and Exchange Commission ("SEC") on April 24, 2020, amended on Form S-3/A that was filed with the SEC on May 15, 2020, and was declared effective by the SEC on May 18, 2020.

A preliminary prospectus supplement relating to the offering was filed with the SEC on September 23, 2021 and is available on the SEC’s website at View Source A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is also available on the SEC’s website at View Source Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On September 28, 2021 panCELLa Inc. and its subsidiary, Implant Therapeutics, reported their partnership with Angios Biotech to evaluate the efficacy of our technologies as incorporated into allogeneic vascular transplants derived from IPSC (Press release, panCELLa, SEP 28, 2021, View Source [SID1234590462]). Angios is developing true blood vessels which are fundamental to engineering tissue and complex cell products for therapy. panCELLa believes our FailSafeTM and Stealth CellsTM technology will guarantee long term engraftment of their cells and ensure an unprecedented level of safety.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our companies are committed to providing the highest quality of cells for therapy. Mahendra Rao, CEO of panCELLa and founder of Implant, notes: "the collaboration of Angios with panCELLa and Implant brings together experts, across two continents, on pluripotent stem cells, gene editing and cell differentiation to treat diseases that require vascular reconstitution. The Stealth CellsTM protect the therapeutic cell treatment from the patient’s immune system offering long-term allo-tolerance without the need for immune suppression. panCELLa’s FailSafeTM is a superior safety switch. Unlike others, it will not be lost or silenced since it is precisely linked to cell division. At any time that cells deregulate or "go rogue" they can be eliminated while still allowing the therapeutic non-dividing cells to continue to do their work.

There is considerable potential for vascular cell therapies as many long-term injuries are currently not adequately served with existing treatment options. Safety and transplant tolerance are two pillars of successful cell therapy, which are both facilitated by the collaboration with panCELLa. "The partnership of panCELLa with Angios is truly accelerating our development of safe allogenic vascular transplants for the treatment of severe vascular diseases." says Gregor Wick, CEO of Angios.

On September 28, 2021 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, repoted that senior leadership plans to present at the following conferences in October (Press release, Genocea Biosciences, SEP 28, 2021, View Source [SID1234590458]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scientific conferences:

Event: AACR: Tumor Immunology and Immunotherapy – Details
Topic: GEN-011: A neoantigen-targeted peripheral blood-derived T cell therapy that has broad neoantigen specificity and high T cell purity while avoiding pro-tumor cells
Format: Poster presentation
Date: Tuesday-Wednesday, October 5-6th
Time: Available throughout the conference

Event: Meeting on the Mesa – Details
Topic: Next-generation neoantigen-targeted solid tumor T cell therapy
Format: Presentation
Date: Tuesday-Thursday, October 12-14th
Time: Available throughout the conference

Event: CMO Summit – Details
Topic: Communicating and Pivoting After a Failed Clinical Trial
Format: Panel
Date: Friday, October 15th
Time:
1:00 p.m. ET

Event: TIL Therapies Digital Summit – Details
Topic: Identification of InhibigensTM May be the Key to Successful T cell Therapies for Solid Tumors
Format: Presentation
Date: Tuesday, October 19th
Time:
11:00 a.m. ET

Event: Neoantigen-Based Therapies Summit – Details
Topic 1: Prioritizing Diversity, Equity, and Inclusion in the Neoantigen Field
Roundtable discussion
Tuesday, October 26th
12:40 p.m. ET
Topic 2:
Responses to Inhibitory Tumor Antigens, InhibigensTM, Suppresses Anti-Tumor Immunity & promote Tumor Growth
Presentation
Wednesday, October 27th
12:30 p.m. ET
Topic 3: Unleashing the Titans: The GEN-011 Neoantigen-Targeted Peripheral T cell Therapy for Solid Tumors
Presentation
Wednesday, October 27th
5:30 p.m. ET

On September 28, 2021 NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase"), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, reported that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 – 5 (Press release, NeuBase Therapeutics, SEP 28, 2021, View Source [SID1234590450]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan 5th Annual Genetic Medicines Conference
Date: Tuesday, October 5th
Time: 11:30 a.m. ET
Location: Webcast link or at the company’s website

On September 28, 2021 Van Andel Institute’s Stephanie Grainger, Ph.D., reported that it has been awarded a $2,375,000, five-year Maximizing Investigators’ Research Award from the National Institute of General Medical Sciences of the National Institutes of Health (Press release, Van Andel Institute, SEP 28, 2021, View Source;utm_medium=rss&utm_campaign=stephanie-grainger-maximizing-investigators-research-award [SID1234590448]). This prestigious grant will support Grainger’s exploration of a critical type of cellular communication that drives healthy development and, when disrupted, can spur cancer, osteoporosis, heart conditions and other diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Called Wnt (and pronounced "wint"), this vital molecular pathway is central to a host of important processes that guide the body’s construction early on and that continue throughout life, such as tissue regeneration during healing.

Stephanie Grainger, Ph.D.

"Much like the foreperson at a construction site, Wnt controls nearly everything the body does throughout development: for example, it communicates where the head should go versus the feet and, in adults, coordinates resources to heal wounds and replenish stem cells," Grainger said. "I am honored to receive this award, which will help us answer longstanding questions that have profound implications for correcting errors in the Wnt pathway as a means to treat disease."

Scientists have long been interested in Wnt as a potential target for new cancer therapies but developing such treatments has proven to be difficult. The problem lies in a lack of insight into the specific interactions between molecules in the vast Wnt network. A better understanding of these interactions could help scientists develop highly targeted approaches that fix specific problems while leaving the rest of the pathway untouched — and producing fewer side effects.

Grainger and her team will focus on two major players in the pathway: Wnt9a and Fzd9b. These molecules, which are found on the outside of cells, interact to convey chemical messages to and from cells. What isn’t clear, Grainger says, is how Wnt9a and Fzd9b enter the cell to deliver their information payload.

"The Wnt pathway operates in a careful balance — too much or too little Wnt activity can have devastating consequences," Grainger said. "Solving the exact mechanism by which Wnt9a and Fzd9b carry out their job could have massive implications for therapeutic development and a ripple effect for understanding other parts of the pathway."

Maximizing Investigators’ Research Awards are highly competitive and provide scientists "with greater stability and flexibility, thereby enhancing scientific productivity and the chances for important breakthroughs," according to the NIGMS. Grainger is the second VAI investigator in the last four years to earn this award. She joined VAI’s Department of Cell Biology in August.

Research reported in this publication was supported by National Institute of General Medical Sciences of the National Institutes of Health under award no. R35GM142779 (Grainger). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.